Pharmafile Logo
Pharmafocus logo
Advanced Search

Bayer

Showing 15 posts of 258 posts found.

regeneron

Regeneron and Ocular Therapeutix to collaborate in potential $315 million deal

October 14, 2016
Medical Communications Bayer, Eyelea, Ocular Therapeutix, Regeneron Pharmaceuticals, wet AMD

Regeneron Pharmaceuticals and Ocular Therapeutix have entered into a deal that will see them collaborate to develop a sustained release …

News
finance

Sanofi lowers Q3 sales figures from 2015

October 13, 2016
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Bayer, Cipro, Plavix, Sanofi, financial results

Sanofi lowered its aggregate sales figure for Q3 2016 from €9.59 billion to €9.46 billion ahead of the release of …

News
janssen_stairs_1

Johnson & Johnson failed to inform FDA over faulty blood testing device in Phase III trial

September 29, 2016
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Bayer, Johnson & Johnson, Xarelto, phase III, warfarin

The British Medical Journal, after its own investigation, found that Janssen knew early into the Phase III trial, known as …

News
eylea-product-box-md

NICE approves Bayer’s Eylea for NHS use

September 28, 2016
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Bayer, Eylea, NICE

Bayer has announced that its Eylea (aflibercept) drug has received a final recommendation from NICE for the treatment of visual …

News

Bayer CEO defends $66 billion Monsanto acquisition

September 20, 2016
Manufacturing and Production, Sales and Marketing Bayer, Werner Baumann, monsanto

Bayer AG’s chief executive Werner Baumann has spoken in defence of the company’s move last week to acquire US agricultural …

News
4420456374_64a3d7e6aa

Top Ten articles in the Pharma Industry this week

September 16, 2016
Medical Communications Bayer, GSK, Gilead, GlaxoSmithKline, J&J, JJ, Pfizer, Roche, Sanofi, Takeda, aspen, google, monsanto

As we come to the end of another week, we’re looking back at an exciting week in the industry; there …

News

Bayer acquires Monsanto in largest-ever deal by a German company

September 14, 2016
Business Services, Manufacturing and Production, Sales and Marketing Bayer, acqusition, monsanto

Bayer and Monsanto have signed a definitive merger agreement under which the German drugmaker will acquire the US agricultural group …

News

Bayer ponders $1.1 billion portfolio sale to fund Monsanto acquisition

September 12, 2016
Business Services, Manufacturing and Production, Sales and Marketing Bayer, acquisition, monsanto

In the latest development in the Bayer-Monsanto saga, the German drugmaker has enlisted the aid of global financial services firm …

News

Bayer takes another shot at Monsanto acquisition

September 6, 2016
Manufacturing and Production, Sales and Marketing Bayer, acqusition, monsanto

Bayer has made another move to acquire US-based Monsanto, raising the price it is prepared to pay in an effort …

News

NICE recommends Bayer’s Xofigo for prostate cancer treatment

September 2, 2016
Medical Communications, Sales and Marketing Bayer, NICE, approval, prostate cancer, recommendation, xofigo

NICE has issued final draft guidance recommending Bayer’s Xofigo (radium-223 dichloride) for the treatment of prostate cancer. Previously, the drug …

News
eylea-product-box-md

NICE recommends Eylea as first-line treatment for sight threatening condition

August 24, 2016
Research and Development, Sales and Marketing Bayer, Eylea, NHS, NICE, first-line treatment

Bayer has announced that the National Institute for Health and Care Excellence (NICE) has recommended Eylea (aflibercept) as a cost-effective …

News
casebia

Bayer’s CRISPR venture opens for business in biotech hub

August 23, 2016
Manufacturing and Production, Research and Development Bayer, casebia, crispr, gene editing, gene-editing

Bayer and CRISPR Therapeutics have joined together to launch Casebia Therapeutics and have chosen Cambridge, Massachusetts, as its base to …

News

Bayer’s liver cancer drug not cost-effective, says NICE

August 19, 2016
Medical Communications, Sales and Marketing Bayer, CDF, NICE, Nexavar, lung cancer

NICE has deemed Bayer’s liver cancer drug Nexavar (sorafenib) as not cost-effective. The drug is currently available on the Cancer …

News

Pharma unit helps boost profits at Bayer

July 27, 2016
Research and Development, Sales and Marketing Bayer, Q2, results

The pharmaceutical division at Bayer was the driving force, as the company announced a 5.7% increase in second quarter profit …

News

Bayer adds extra $2 billion to Monsanto bid

July 15, 2016
Medical Communications, Sales and Marketing Bayer, monsanto

German pharma company Bayer (ETR: BAYN) have upped their bid for Monsanto (NYSE: MON) to $64 billion, putting pressure on …

News

Latest content

GSK shares data from global shingles survey

December 1, 2023

AbbVie to acquire ImmunoGen for approximately $10.1bn

December 1, 2023

FDA accepts NDA for Karuna’s schizophrenia treatment

November 30, 2023

Vivos Therapeutics gains FDA 510(k) clearance for sleep apnea treatment device

November 30, 2023

Tolremo doses first patient in phase 1 trial for drug to combat transcriptional cancer drug resistance

November 29, 2023